Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancer

Abstract Background Several studies have shown the advantage of delayed-time-point imaging with 18F-FDG-PET/CT to distinguish malignant from benign uptake. This may be relevant in cancer diseases with low metabolism, such as breast cancer. We aimed at examining the change in SUV from 1 h (1h) to 3 h...

Full description

Bibliographic Details
Main Authors: Christina Baun, Kirsten Falch, Oke Gerke, Jeanette Hansen, Tram Nguyen, Abass Alavi, Poul-Flemming Høilund-Carlsen, Malene G. Hildebrandt
Format: Article
Language:English
Published: BMC 2018-05-01
Series:BMC Medical Imaging
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12880-018-0254-8
id doaj-bbc00e9a5a024d8cb04113342e520cea
record_format Article
spelling doaj-bbc00e9a5a024d8cb04113342e520cea2020-11-24T21:09:58ZengBMCBMC Medical Imaging1471-23422018-05-0118111010.1186/s12880-018-0254-8Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancerChristina Baun0Kirsten Falch1Oke Gerke2Jeanette Hansen3Tram Nguyen4Abass Alavi5Poul-Flemming Høilund-Carlsen6Malene G. Hildebrandt7Department of Nuclear Medicine, University HospitalDepartment of Nuclear Medicine, University HospitalDepartment of Nuclear Medicine, University HospitalDepartment of Nuclear Medicine, University HospitalDepartment of Nuclear Medicine, University HospitalUniversity of PennsylvaniaDepartment of Nuclear Medicine, University HospitalDepartment of Nuclear Medicine, University HospitalAbstract Background Several studies have shown the advantage of delayed-time-point imaging with 18F-FDG-PET/CT to distinguish malignant from benign uptake. This may be relevant in cancer diseases with low metabolism, such as breast cancer. We aimed at examining the change in SUV from 1 h (1h) to 3 h (3h) time-point imaging in local and distant lesions in patients with recurrent breast cancer. Furthermore, we investigated the effect of partial volume correction in the different types of metastases, using semi-automatic quantitative software (ROVER™). Methods One-hundred and two patients with suspected breast cancer recurrence underwent whole-body PET/CT scans 1h and 3h after FDG injection. Semi-quantitative standardised uptake values (SUVmax, SUVmean) and partial volume corrected SUVmean (cSUVmean), were estimated in malignant lesions, and as reference in healthy liver tissue. The change in quantitative measures from 1h to 3h was calculated, and SUVmean was compared to cSUVmean. Metastases were verified by biopsy. Results Of the 102 included patients, 41 had verified recurrent disease with in median 15 lesions (range 1-70) amounting to a total of 337 malignant lesions included in the analysis. SUVmax of malignant lesions increased from 6.4 ± 3.4 [0.9-19.7] (mean ± SD, min and max) at 1h to 8.1 ± 4.4 [0.7-29.7] at 3h. SUVmax in breast, lung, lymph node and bone lesions increased significantly (p < 0.0001) between 1h and 3h by on average 25, 40, 33, and 27%, respectively. A similar pattern was observed with (uncorrected) SUVmean. Partial volume correction increased SUVmean significantly, by 63 and 71% at 1h and 3h imaging, respectively. The highest impact was in breast lesions at 3h, where cSUVmean increased by 87% compared to SUVmean. Conclusion SUVs increased from 1h to 3h in malignant lesions, SUVs of distant recurrence were in general about twice as high as those of local recurrence. Partial volume correction caused significant increases in these values. However, it is questionable, if these relatively modest quantitative advances of 3h imaging are sufficient to warrant delayed imaging in this patient group. Trial registration ClinicalTrails.gov NCT01552655. Registered 28 February 2012, partly retrospectively registered.http://link.springer.com/article/10.1186/s12880-018-0254-8FDG-PET/CTBreast cancerDelayed-time-pointStandardised uptake valuesPartial volume correction
collection DOAJ
language English
format Article
sources DOAJ
author Christina Baun
Kirsten Falch
Oke Gerke
Jeanette Hansen
Tram Nguyen
Abass Alavi
Poul-Flemming Høilund-Carlsen
Malene G. Hildebrandt
spellingShingle Christina Baun
Kirsten Falch
Oke Gerke
Jeanette Hansen
Tram Nguyen
Abass Alavi
Poul-Flemming Høilund-Carlsen
Malene G. Hildebrandt
Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancer
BMC Medical Imaging
FDG-PET/CT
Breast cancer
Delayed-time-point
Standardised uptake values
Partial volume correction
author_facet Christina Baun
Kirsten Falch
Oke Gerke
Jeanette Hansen
Tram Nguyen
Abass Alavi
Poul-Flemming Høilund-Carlsen
Malene G. Hildebrandt
author_sort Christina Baun
title Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancer
title_short Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancer
title_full Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancer
title_fullStr Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancer
title_full_unstemmed Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancer
title_sort quantification of fdg-pet/ct with delayed imaging in patients with newly diagnosed recurrent breast cancer
publisher BMC
series BMC Medical Imaging
issn 1471-2342
publishDate 2018-05-01
description Abstract Background Several studies have shown the advantage of delayed-time-point imaging with 18F-FDG-PET/CT to distinguish malignant from benign uptake. This may be relevant in cancer diseases with low metabolism, such as breast cancer. We aimed at examining the change in SUV from 1 h (1h) to 3 h (3h) time-point imaging in local and distant lesions in patients with recurrent breast cancer. Furthermore, we investigated the effect of partial volume correction in the different types of metastases, using semi-automatic quantitative software (ROVER™). Methods One-hundred and two patients with suspected breast cancer recurrence underwent whole-body PET/CT scans 1h and 3h after FDG injection. Semi-quantitative standardised uptake values (SUVmax, SUVmean) and partial volume corrected SUVmean (cSUVmean), were estimated in malignant lesions, and as reference in healthy liver tissue. The change in quantitative measures from 1h to 3h was calculated, and SUVmean was compared to cSUVmean. Metastases were verified by biopsy. Results Of the 102 included patients, 41 had verified recurrent disease with in median 15 lesions (range 1-70) amounting to a total of 337 malignant lesions included in the analysis. SUVmax of malignant lesions increased from 6.4 ± 3.4 [0.9-19.7] (mean ± SD, min and max) at 1h to 8.1 ± 4.4 [0.7-29.7] at 3h. SUVmax in breast, lung, lymph node and bone lesions increased significantly (p < 0.0001) between 1h and 3h by on average 25, 40, 33, and 27%, respectively. A similar pattern was observed with (uncorrected) SUVmean. Partial volume correction increased SUVmean significantly, by 63 and 71% at 1h and 3h imaging, respectively. The highest impact was in breast lesions at 3h, where cSUVmean increased by 87% compared to SUVmean. Conclusion SUVs increased from 1h to 3h in malignant lesions, SUVs of distant recurrence were in general about twice as high as those of local recurrence. Partial volume correction caused significant increases in these values. However, it is questionable, if these relatively modest quantitative advances of 3h imaging are sufficient to warrant delayed imaging in this patient group. Trial registration ClinicalTrails.gov NCT01552655. Registered 28 February 2012, partly retrospectively registered.
topic FDG-PET/CT
Breast cancer
Delayed-time-point
Standardised uptake values
Partial volume correction
url http://link.springer.com/article/10.1186/s12880-018-0254-8
work_keys_str_mv AT christinabaun quantificationoffdgpetctwithdelayedimaginginpatientswithnewlydiagnosedrecurrentbreastcancer
AT kirstenfalch quantificationoffdgpetctwithdelayedimaginginpatientswithnewlydiagnosedrecurrentbreastcancer
AT okegerke quantificationoffdgpetctwithdelayedimaginginpatientswithnewlydiagnosedrecurrentbreastcancer
AT jeanettehansen quantificationoffdgpetctwithdelayedimaginginpatientswithnewlydiagnosedrecurrentbreastcancer
AT tramnguyen quantificationoffdgpetctwithdelayedimaginginpatientswithnewlydiagnosedrecurrentbreastcancer
AT abassalavi quantificationoffdgpetctwithdelayedimaginginpatientswithnewlydiagnosedrecurrentbreastcancer
AT poulflemminghøilundcarlsen quantificationoffdgpetctwithdelayedimaginginpatientswithnewlydiagnosedrecurrentbreastcancer
AT maleneghildebrandt quantificationoffdgpetctwithdelayedimaginginpatientswithnewlydiagnosedrecurrentbreastcancer
_version_ 1716756805813534720